With obesity now understood to be a chronic health condition, it’s time for plan sponsors to revisit their approach to weight loss medications, said Philippe Laplante, principal for pension and benefits at Eckler Ltd., during a session at Benefits Canada’s 2024 Vancouver Benefits Summit in May. The conversation about extending coverage to new, high-cost anti-obesity […]
Roughly a third (34 per cent) of employers in the U.S. are providing coverage for glucagon-like peptide-1 medications for both diabetes care and weight-loss management in 2024, up from 26 per cent in 2023, according to a new survey by the International Foundation of Employee Benefit Plans. However, the survey, which polled more than 270 U.S. employers, found more […]
An article detailing a stark increase in the use of obesity medications among Canadian employer-sponsored benefits plan members was the most-read article on BenefitsCanada.com this week. Here are the top five human resources, benefits, pension and investment stories of the past week: 1. Claims for obesity drugs increased 42% in 2023, 92% since 2020: report 2. How […]
When considering whether to cover Wegovy, an obesity medication, it’s important for plan sponsors to weigh increased short-term costs with long-term savings, while considering alternative treatments that are also available, says Philippe Laplante, a principal at Eckler Ltd. Plan sponsors that decide to cover Wegovy, which launched in Canada last month, could see a significant cost […]
The use of obesity medications among Canadian employer-sponsored benefits plan members has grown substantially, with claims increasing 42 per cent in 2023 and roughly 92 per cent since 2020, according to a new report by Manulife Financial Corp. The report, based on aggregate claims data, found more women are using obesity drugs than men (79 […]
An article on considerations for plan sponsors ahead of the rollout of a new generation of obesity drugs was the most-read article on BenefitsCanada.com. Here are the top five human resources, benefits, pension and investment stories of the past week: 1. What plan sponsors should know ahead of rollout of new obesity drugs in Canada 2. What’s […]
A new generation of glucagon-like peptide-1 drugs approved for the treatment of obesity will soon be available in Canada, presenting an opportunity for plan sponsors to meet members’ health and wellness needs. It’s important for employers to consider meeting with their insurer now to find out how the rollout of these drugs will affect their […]
While medications for three interconnected chronic conditions — cardiovascular disease, diabetes and obesity — represent a growing proportion of employers’ drug spend, there’s plenty that can be done to help employees’ slow the progression of these conditions while managing drug plan costs, said Joyce Wong, director of clinical services at Express Scripts Canada, during Benefits […]
It’s important for private payers and employers to be nimble and innovative to support plan members seeking access to novel drugs and treatments by addressing common hurdles within their own drug plans, said John Adams, chair of the board of directors for patient advocacy group Best Medicines Coalition, during a session at Benefits Canada’s 2023 Face […]
A story about the B.C. Lottery Corp.’s new inclusive holiday program was the most-read story on BenefitsCanada.com this week. Here are the top five human resources, benefits, pension and investment stories of the past week. 1. BCLC allowing employees to swap statutory holidays for personal, cultural days of significance 2. My Take: Obesity should be treated like […]